KAPAKairos Pharma Ltd. Common Stock
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the tr…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News Bayer’s share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on several measures. This raises the question of how much of the recent optimism is already reflected in the price. Bayer has returned 70.4% over the past year, which puts recent gains front and center for anyone assessing what is already priced in. The new collaboration with Kairos Pharma around XOFIGO in metastatic prostate cancer can support sentiment around... | ||
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership focuses on combination treatments for metastatic prostate cancer. The alliance with Henry Ford Health covers cardiovascular, oncology, and women’s health research using advanced data and clinical technologies. Bayer, traded under XTRA:BAYN, is adding these research deals alongside a share price... | ||
 Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally. | ||
 Kairos Pharma reports positive data from Phase II prostate cancer treatment trial The trial consisted of subjects who had not responded to at least one form of hormone therapy previously. | ||